Galvani Bioelectronics
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Accession announces major UK market access consulting milestone
February 5th 2025: Today Accession Healthcare Consulting Ltd (Accession) has announced the achievement of a major consulting milestone as it enters its 15th year as a specialist provider of UK...
CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development
The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023
Kate Shaw comments the appointment of an independent review on clinical trials in the UK.
The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five...
FDA approves GSK’s Priorix vaccine for measles, mumps and rubella
The vaccine has been approved to use in those aged 12 months and above
Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn
Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis
GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines
The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies
WHO has recommended GSK’s malaria vaccine for children
This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children
GSK beats expectations thanks to strong vaccine sales in Q2
GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine
EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine
Rolling review launched based on preliminary results from lab studies and early clinical studies
GSK reveals plans for £400m R&D facility expansion in England
GSK has formally started the process of seeking a development partner for the expansion plans
GSK supports CEO Emma Walmsley following Elliott’s demands for leadership overhaul
GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business